A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Latest Information Update: 02 Mar 2026
At a glance
- Drugs GSK 5459248; PCV 20
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors GSK
Most Recent Events
- 02 Mar 2026 New trial record